References
- World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization. Background paper on Dengue Vaccines prepared by the SAGE working group on dengue vaccines and the WHO secretariat. [cited 2016 Aug 12]. Retrieved from http://www.who.int/immunization/sage/meetings/2016/april/presentations_background_docs/en/
- Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195–1206.
- Halstead SB, Russell PK. Protective and immunological behavior of yellow fever dengue chimeric vaccine. Vaccine. 2016;34(14):1643–1647.
- Ferguson N, Rodríguez-Barraquer I, Dorigatti I, et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science. 2016;353:1033–1036.
- Coudeville L, Baurin N, L’Azou M, et al. Potential impact of dengue vaccination: insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine. 2016;34:6426–6435. DOI:10.1016/j.vaccine.2016.08.050
- Aguiar M, Stollenwerk N, Halstead SB. The impact of the newly licensed dengue vaccine in endemic countries. PLoS Negl Trop Dis. 2016;10(12):e0005179. doi:10.1371/journal.pntd.0005179
- Aguiar M, Stollenwerk N, Halstead SB. The risks behind Dengvaxia recommendation. Lancet Infect Dis. 2016;16:882.